"Taiwan Pharmaceuticals & Healthcare Report Q4 2013" Published
Taiwan's ageing population continues to be a key driver of pharmaceutical sales in the country. However, we note that deficits in the national health insurance account will act as a downside risk to pharmaceutical firms as extensive price cuts on medicines may be enforced to contain costs.
View full press release